抗大肠癌组织差异表达蛋白(SCAP47)抗体的制备及初步应用

制备一种新的大肠癌组织差异表达蛋白质抗体(抗SCAP47)，用于检测大肠癌相关肿瘤抗原SCAP47。采用本室制备的大肠癌组织差异表达蛋白质(SCAP47)免疫新西兰纯种兔，制备兔抗SCAP47抗体，用双向免疫扩散法和ELISA法测定抗体效价；并用ELISA法检测129例患者的胃肠道肿瘤和疾病及正常对照组织的可溶性SCAP47抗原。用SCAP47抗原免疫新西兰纯种兔，获得抗SCAP47抗体，经检测其最高效价：双向免疫扩散法为1：32；ELISA法为1：6400。129例患者的胃肠道肿瘤和疾病及正常对照组织可溶性SCAP47抗原ELISA法检测结果显示：诊断大肠癌的敏感性52．4％，特异性95．4％，阳性预示值84．6％，阴性预示值80．6％，似然比11．4，约登指数0．47。本实验制备的抗SCAP47抗体是一种新的大肠癌相关抗原SCAP47抗体。由于SCAP47不同于CEA、P^27、CCA等大肠癌肿瘤标志物，且在大肠癌中呈现高度表达，推测其可能是一种新的大肠癌相关抗原。因此，制备抗SCAP47抗体为用于多种指标联合检测早期大肠肿瘤提供了一种新的检测工具。

Prepartion and Application of the Differential Expression Protein for Colorectal Cancer

To produce a new antibody against associated espression protein for colorectal cancer (CRC), then using it to detect the associated antigen SCAP47 for CRC, 3 New Zealand white rabbits were injected by the differential expression protein for CRC, which isoleted from CRC tissues. The serum was spearated and collected from these rabbits, then the titer of polyclonal antibodies (PcAb) was detected by enzymelinked immunosorbent assay (ELISA) and double diffussion precipitation test. Moreover, the soluble SCAP47 antigen was determined by ELISA in 129 patients with gastroenteritic tumor. The title of PcAb was 1 : 32 by double diffussion precipitation test and 1 : 6400 by ELISA. To diagnose CRC with SCAP4, the sensitivity, specificity,positive protective value, negatine protective protective value and coincidence rate attained 52.4%, 95.4%, 84.6%, 80.6% and 11.4, respectively, and Youden's index was 0.47. The findings support that the isolated SCAP47 protein may associates with gonesis and developing of CRC.